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Background: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on
receptor activator of nuclear factor κ-B ligand (RANKL)/receptor activator of nuclear factor κ-B (RANK)/Osteoprotegerin
(OPG) system in rheumatoid arthritis (RA) and its anti-osteoclastogenesis mechanism.
Methods: The expression of OPG, RANK and RANKL in CD3+ T leukomonocytes in both peripheral blood and synovial
fluid of RA patients was evaluated by flow cytometry. The levels of interleukin (IL) 1β, IL-6, IL-10, IL-21 and IL-23 in the
supernatants of peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) were
assayed by ELISA. Tartaric acid phosphatase (TRAP) staining was used to identify the osteoclast-like cells derived from
RAW264.7. Western blotting analysis was used to check the downstream molecules of RANKL.
Results: LLDT-8 increased the rate of OPG expression in CD3+ T leukomonocytes in peripheral blood as well as the
ratio of OPG/RANKL in both peripheral blood and synovial fluid. LLDT-8 inhibited IL-1β, IL-6, IL-21 and IL-23 secretion,
but promoted the secretion of IL-10 in the supernatants of PBMCs and SFMCs. In addition, LLDT-8 decreased the
number of TRAP-positive cells derived from RAW264.7 in the presence of RANKL and M-CSF. Furthermore, LLDT-8 also
inhibited the expression of p-IκB, a key regulator of RANKL signaling pathway.
Conclusions: LLDT-8 exerts its anti-osteoclastogenesis effect in RA probably through regulating RANKL/RANK/OPG
system and its downstream signaling pathway as well as cytokine productions.
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Rheumatoid arthritis (RA) is a kind of autoimmune dis-
ease, which usually results in a chronic, systemic inflam-
matory disorder that may affect many tissues and
organs, especially joints. RA is characterized by inflam-
matory synovitis and destruction of cartilage and bone,
which usually leads to substantial loss of function and
mobility. How to delay with or prevent bone destruction
caused by RA, and improve the life quality of patients
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unless otherwise stated.[1]. Tripterygium Wil’fordii Hook.F, belonging to plants
of the genus Euonymus Corey Gong, is a traditional
Chinese medicine, the extracts of which have a variety of
pharmacological effects, such as anti-inflammatory, anti-
biosis, antifertility, immunosuppression, anti tumor and
etc. Thus, they are widely used in the treatment of
rheumatic disease, autoimmune disease, organ trans-
plantation, nephroma, asthma and tumor [2]. Among
the extracts, Ttriptolide is the most active compound,
which has strong immunosuppressive activity. However,
Ttriptolide could not be directly used in clinic because
of its biological toxicity and narrow therapeutic window
[3]. (5R)-5-hydroxytriptolide (LLDT-8) is a new analog
of Ttriptolide, which has been qualified and optimized
in structure, and shows lower cytotoxicity and relatively
higher immunosuppressive activity. In our previoushis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,





Taking non-steroidal anti-inflammatory drugs 28
Taking 1 disease modifying antirheumatic drug 4
Taking 2 disease modifying antirheumatic drug 17
Taking≥ 3 disease modifying antirheumatic drug 4
Taking glucocorticoid 13
Taking biologics 3
Disease modifying antirheumatic drugs include methotrexate, leflunomide,
sulfasalazine, penicillamine, hydroxychloroquine, and some herb extracts such
as total glucosides of paeony, tripterygium glycosides and the extract of Caulis
Sinomenii. Dose of glucocorticoid equals to prednisone 2–10 mg daily.
Biologics include Etanercept (2 cases) and Infliximab (1 case).
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reduced compared with triptolide. General speaking, it
showed a 122-fold lower cytotoxicity in vitro and 10-fold
lower acute toxicity in vivo [4]. Previous studies also dem-
onstrated that LLDT-8 has a variety of immunosuppres-
sive activities and significant therapeutic effects in vitro
and in vivo [5-7]. However, how LLDT-8 influences osteo-
clastogenesis is still unknown.
The purpose of our study was to assess the effects of
LLDT-8 on RANK/RANKL/OPG signaling pathway and
osteoclastogenesis. Our work suggested that LLDT-8 up-
regulated OPG expression in CD3+T leukomonocytes in
peripheral blood as well as the ratio of OPG/RANKL in
both peripheral blood and synovial fluid, and it also
inhibited inflammatory cytokine secretion in the super-
natants of PBMCs and SFMCs. Besides, LLDT-8 may re-
duce osteoclastogenesis by inhibiting NF-κB signaling.
These results guarantee a good prospect in further clin-




Thirty two specimens in this study were obtained from
Shanghai Guanghua Hospital, among which 21 speci-
mens were peripheral blood and 11 specimens were syn-
ovial fluid. The study was approved by the Research
Ethics Board of Shanghai Guanghua Hospital, and writ-
ten informed consents were obtained from all patients.
The 32 specimens were from 29 RA patients, and 27
were female. Patients aged 55.55 ± 12.43 years old, and
the duration of illness were in the span of 11.23 ±
9.82 years. All the patients fulfilled the ACR 1987 re-
vised classification criteria for RA. Disease activity score
in 28 joints (DAS28), which recommended by European
League Against Rheumatism (EULAR), was used to
evaluate the disease activity of RA, and 28 patients were
in disease activity (DAS28 ≥ 2.6) (Table 1). Besides, 28
patients had taken drugs which used to treat RA before
the specimens were obtained (Table 2).Table 1 Disease activity evaluated by DAS28





DAS28(ESR) = 0.56*(TJC28) + 0.28*(SJC28) + 0.014*VAS + 0.70*ln(ESR). TJC,
means the number of tender joints of 28 counted; SJC, means the number of
swollen joints of 28 counted; VAS, the score which scaled out by the subject
on 100 mm Visual analog scale to match with joint pain [8]. DAS28 < 2.6,
indicated Remission; 2.6 ≤ DAS28 < 3.2, indicated low disease activity;
3.2 ≤ DAS28 ≤ 5.1, indicated moderate disease activity; DAS28 > 5.1, indicated
high disease activity [9].Cell line
Murine RAW264.7 cell line was obtained from Chinese
Academy of Sciences, Shanghai Institute of Materia
Medica (Shanghai, China).
Reagents
LLDT-8 was obtained from Shanghai Pharmaceutical
Group (Shanghai, China). RPMI 1640 medium and
DMEM were purchased from Hyclone (USA). Fetal bo-
vine serum was purchased from Gibco (USA). Lympho-
cyte separation medium was purchased from MP
Biomedicals (USA). TRAP staining kit was purchased
from Sigma-Aldrich (USA). Rat soluble RANK ligand
and rat M-CSF were purchased from Peprotech (USA).
Antibodies specific for phospho-IκB, phospho-p38,
phospho-JNK, phospho-ERK and phospho-Akt were
purchased from Cell Signaling Technology (USA).
PBMC and SFMC isolation
Aseptic and heparin anticoagulant peripheral blood or
synovial fluid was prepared, and two-fold diluted by
PBS, then transferred to 15 ml centrifuge tube with
LSM, and centrifuged at 2500 rpm for 20 min at room
temperature. The white mononuclear cells were aspi-
rated, and then washed with PBS (at 2000 rpm for
10 min). The cell pellets were collected, and diluted to
suitable concentration with culture medium (RPMI 1640
with 10% FBS).
Flow cytometry
PBMCs or SFMCs were separated, and seeded at a dens-
ity of 1 × 106 cells/well in 96-well plates in the presence
of LLDT-8 (0, 25 and 50 nM, respectively) for 24 hours
in incubator. The cells were harvested and washed with
FACS washing buffer followed by incubation with anti-
human CD3 (eBioscience, USA) and OPG (bony-1,
SANTA CRUZ Biotec, USA) at 4°C for 20 min. After
Shen et al. BMC Complementary and Alternative Medicine  (2015) 15:77 Page 3 of 10washed by FACS washing buffer, the cells were incubated
with goat anti-rat IgG-FITC (SANTA CRUZ) at 4°C for
20 min, then PE conjugated anti-human RANK (R&D
Systems, USA), APC conjugated anti-human RANKL
(R&D Systems) and Percp conjugated anti-human CD3
(Miltenyi Biotec, Germany) were added respectively, and
incubated at 4°C for 20 min. Then the cells were detected
by flow cytometry.ELISA
PBMCs or SFMCs were separated, and seeded at a dens-
ity of 1 × 106 cells/well in 96-well plates in the presence
of anti-human CD3 (0.4 μg/ml) and LLDT-8 (0, 12.5, 25,
and 50 nM, respectively) for 48 hours in incubator. The
cell culture supernatants were harvested and the levels
of cytokines (IL-1β, IL-6, IL-21, IL-23 and IL-10) wereFigure 1 LLDT-8 up-regulated OPG expression and increased the ratio
RA patients. PBMCs were isolated from peripheral blood of RA patients an
respectively) for 24 hours, then stained and detected by flow cytometry. (A
OPG expression on CD3+ T leukomonocyte in the three groups. (C) The rat
*p < 0.05 compared to the control group (0 nM).assayed by ELISA kits (eBioscience). All the processes
were followed according to the manufacturer’s instructions.
In the end a standard curve from the data produced from
the serial dilutions with concentration on the X axis (log
scale) vs absorbance on the Y axis (linear) was drawn to
calculate the concentration of the protein.Osteoclast formation
RAW264.7 cells were grown in DMEM supplemented
with 10% FBS and 1% penicillin/streptomycin. For differ-
entiation of osteoclasts, RAW264.7 cells were seeded at
a density of 2 × 104 cells/well in 24-well plates, and cul-
tured in the presence of RANKL (50 ng/ml), M-CSF
(50 ng/ml) and LLDT-8 (0, 12.5, 25 and 50 nM, respect-
ively) for 6 days. The culture medium was replaced every
3 days. The cells were stained by TRAP kit according toof OPG/RANKL on CD3+ T leukomonocyte in peripheral blood of
d treated with various concentrations of LLDT-8 (0, 25 nM and 50 nM,
) The psuedocolor plots of OPG, RANK and RANKL. (B) The rate of
io of OPG to RANKL on CD3+ T leukomonocyte in the three groups.
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Osteoclast formation was determined to be TRAP-positive
staining multinuclear cells using light microscopy. The
total number of TRAP-positive cells in each well was
counted.
Western blotting analysis
RAW264.7 cells were seeded at a density of 1 × 107
cells/well in 6-well plates in DMEM supplemented with
10% FBS and 1% penicillin/streptomycin. After cell at-
tachment, the culture medium was replaced by DMEM
supplemented with LLDT-8 (0 and 50 nM, respectively)
for 4 hours, then the cells were induced by culture
medium supplemented with 50 ng/ml RANKL for 0, 10,
30 and 60 min, respectively. The cells were collected and
lysed by 1 nM PMSF SDS on ice for 30 min. The cellular
lysates were loaded, and proteins were separated onFigure 2 LLDT-8 increased the ratio of OPG/RANKL in synovial fluid o
and treated with various concentrations of LLDT-8 (0, 25 and 50 nM, respe
(A) The psuedocolor plots of OPG, RANK and RANKL. (B) The rate of OPG e
of OPG/RANKL on CD3+ T cells in the three groups. *p < 0.05 compared toSDS-PAGE and transferred to nitrocellulose filter. The
blots were blocked with 5% BSA TBST for 1 h at room
temperature, then probed with rabbit anti-mouse anti-
bodies against p-IκB, p-P38, p-JNK, p-ERK, p-Akt
(1:1000) and GAPDH (1:6000) overnight at 4°C. After
five washes, the blots were subsequently incubated with
a HRP-linked secondary antibody (1:2500) for 90 min
at room temperature. The blots were visualized by
ECLTM Prime Western Blotting Detection Reagent.
The pictures were adorned by ImageQuant software
(Photoshop CS2).
Statistics
The values given are mean ± SEM. The difference be-
tween the experimental groups and the control was
assessed by one-way analysis of variance (ANOVA) with
LSD test. The difference is significant if p < 0.05.f RA patients. SFMCs were isolated from synovial fluid of RA patients
ctively) for 24 hours, then stained and detected by flow cytometry.
xpression on CD3+ T leukomonocyte in the three groups. (C) The ratio
the control group (0 nM).
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LLDT-8 up-regulated OPG expression on CD3+ T
leukomonocyte, and increased the ratio of OPG to RANKL
We isolated PBMCs from blood sample of RA patients,
incubated them with various concentrations of LLDT-8
(0, 25 nM and 50 nM) for 24 hours, and examined the
OPG, RANK and RANKL expression on the cells. The
results showed that LLDT-8 up-regulated OPG expression
on CD3+ T leukomonocyte in peripheral blood at doses of
25 nM and 50 nM (Figure 1B), and increased the ratio of
OPG/RANKL at the dose of 50 nM (Figure 1C). However,
there was no significant difference between RANKL or
RNAK expression in the LLDT-8 treated groups and the
control group.
We also isolated SFMCs from synovial fluid of RA pa-
tients, and examined the OPG, RANK and RANKL ex-
pression on these cells treated by the same method as
PBMCs. The results showed LLDT-8 (50 nM) increased
the ratio of OPG/RANKL on CD3+ T cells in synovial
fluid (Figure 2C), and there was an upward trend on
OPG expression (Figure 2B). However, there was noFigure 3 LLDT-8 inhibited secretion of IL-1β, IL-6, IL-21 and IL-23, but
from peripheral blood of RA patients. PBMCs were isolated from periph
CD3 (0.4 μg/ml) and LLDT-8 (0, 12.5, 25 and 50 nM, respectively) for 48 hou
the proteins were detected by ELISA. (A) The levels of IL-1β in the superna
the four groups. (C) The levels of IL-21 in the supernatants of the four grou
(E) The levels of IL-10 in the supernatants of the four groups. *p < 0.05, **pdistinct effect of LLDT-8 on the rate of RANKL or
RANK expression on CD3+ T cells in synovial fluid.
All these data suggested LLDT-8 may up-regulate
OPG expression on CD3+ T leukomonocyte in periph-
eral blood of RA patients, and increase the ratio of
OPG/RANKL on CD3+ T leukomonocyte in both per-
ipheral blood and synovial fluid.
LLDT-8 inhibited IL-1β, IL-6, IL-21 and IL-23 secretion, but
promoted the secretion of IL-10
To evaluate the effect of LLDT-8 on the secretion of cy-
tokines in PBMCs from RA patients, the cells were cul-
tured in the presence of anti-human CD3 (0.4 μg/ml)
with various concentrations of LLDT-8 (0, 12.5, 25 and
50 nM, respectively) for 48 hours. The cell culture su-
pernatants were harvested, and the levels of cytokines
(IL-1β, IL-6, IL-21, IL-23 and IL-10) were assayed by
ELISA. The results showed that the concentrations of
IL-1β, IL-6, IL-21 and IL-23 in LLDT-8 treated groups
were lower than those in the control group. This sug-
gested LLDT-8 can reduce the levels of IL-1β, IL-6, IL-21promoted the secretion of IL-10 in the supernatants of PBMCs
eral blood of RA patients and cultured in the presence of anti-human
rs in incubator. The cell supernatants were harvested, and the levels of
tants of the four groups. (B) The levels of IL-6 in the supernatants of
ps. (D) The levels of IL-23 in the supernatants of the four groups.
< 0.01, ***p < 0.001, compared to the control group (0 nM).
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itionally, the concentrations of IL-10 in LLDT-8 treated
groups were higher than those in the control group, which
indicated that LLDT-8 could increase the level of IL-10 in
the cell supernatants (Figure 3E). All these data suggested
that LLDT-8 inhibited PBMCs secreting IL-1β, IL-6, IL-21
and IL-23; on the other hand it could promote the secre-
tion of IL-10 in PBMCs.
Besides, we also detected the effect of LLDT-8 on the
secretion of cytokines in SFMCs from RA patients, and
found that LLDT-8 reduced the levels of IL-1β, IL-6,
and IL-21 in the supernatants of SFMCs (Figure 4A-C).
However, we did not find any distinct effect of LLDT-8 on
the secretion of IL-23 (Figure 4D). We also found that
LLDT-8 increased the level of IL-10 in the cell
supernatants (Figure 4E). Above all, the results demon-
strated that LLDT-8 could inhibite SFMCs secreting IL-1β,
IL-6 and IL-21, but promoted IL-10 secretion in SFMCs.
LLDT-8 decreased the number of TRAP-positive cells
To detect the effect of LLDT-8 on RANKL-induced os-
teoclastogenesis, RAW264.7 cells were cultured in the
presence of RANKL (50 ng/ml) and M-CSF (50 ng/ml)
with or without various concentrations of LLDT-8 forFigure 4 LLDT-8 inhibited secretion of IL-1β, IL-6 and IL-21, but promot
synovial fluid of RA patients. SFMCs were isolated from synovial fluid of RA
and LLDT-8 (0, 12.5, 25 and 50 nM, respectively) for 48 hours in incubator. The
detected by ELISA. (A) The levels of IL-1β in the supernatants of the four grou
levels of IL-21 in the supernatants of the four groups. (D) The level of IL-23 in th
of the four groups. **p< 0.01, ***p< 0.001, compared to the control group (0 n6 days. The total number of TRAP-positive cells in each
well was counted. We found that the cells showed en-
larged volume and irregular shape, and the staining was
burgundy. The number of osteoclasts increased grad-
ually since 72 h (Figure 5A), and reached its top amount
at day 6 (Figure 5B). A small number of TRAP-positive
cells were observed at day 6 in the presence of RANKL
(50 ng/ml) and M-CSF (50 ng/ml) with 50 nM LLDT-8
(Figure 5C). The cells without RANKL and M-CSF indu-
cing, were unable to transform into TRAP-positive osteo-
clasts (Figure 5D). In comparison with the non-treated
group, LLDT-8 reduced the number of TRAP-positive os-
teoclasts at 48 h (Figure 6B), and significantly decreased
the number of TRAP-positive osteoclasts from the 3rd
day to the 6th day (Figure 6C & D). We did not observe
any significant difference between LLDT-8-treated groups
and the non-treated group at 24 h (Figure 6A).
LLDT-8 inhibited RANKL- induced NF-κB activation
To reveal the mechanism of LLDT-8 on inhibiting osteo-
clastogenesis, we tested the effect of LLDT-8 on the
downstream signaling pathways of RANKL by Western
blotting. RANKL significantly increased the levels of
phosphorylation of I-κB, P38, JNK, ERK and Akt in aed the secretion of IL-10 in the supernatants of SFMCs from
patients and cultured in the presence of anti-human CD3 (0.4 μg/ml)
cell supernatants were harvested and the levels of the proteins were
ps. (B) The levels of IL-6 in the supernatants of the four groups. (C) The
e supernatants of the four groups. (E) The levels of IL-10 in the supernatants
M).
Figure 5 Cell morphology of RAW264.7. RAW264.7 cells were cultured in the presence of RANKL (50 ng/ml) and M-CSF (50 ng/ml) with various
concentrations of LLDT-8 (0, 12.5, 25 and 50 nM, respectively) for 6 days, then the cells were fixed and stained with TRAP kit on day 1, 2, 3 and 6.
The cell morphology were observed using light microscopy, The number of TRAP-positive staining multinuclear cells increased gradually since
72 h (A), and reached the top amount at day 6 (B). A small number of TRAP-positive cells were observed at day 6 in the presence of RANKL
(50 ng/ml) and M-CSF (50 ng/ml) with 50 nM LLDT-8 (C). TRAP-positive cells were not observed in the culture medium without RANKL and
M-CSF (D). (A-C) 400-fold amplification, bar = 25 μm; (D) 200-fold amplification, bar = 50 μm.
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group, LLDT-8 markedly inhibited the expression of p-
IκB induced by RANKL. However, it had little effect on
the expression of p-P38、p-JNK、p-ERK and p-Akt in-
duced by RANKL (Figure 7B).
Discussion
RANK, RANKL and OPG, are essential for the differen-
tiation and activation of osteoclasts. RANKL interacts
with its receptor RANK locating on the osteoclast mem-
brane to initiate osteoclastic activation, subsequently
induces osteoclasts differentiation and inhibits their
apoptosis. OPG acts as an endogenous decoy receptor
that competitively inhibits osteoclasts differentiation
through its interaction with RANKL [10]. However, the
balance of RANKL/RANK/OPG signaling pathway is
broken in RA patients. Compared with healthy individ-
uals, RA patients showed significantly higher serum
levels of RANKL, lower levels of OPG, and decreased
OPG/RANKL ratio in peripheral blood. Moreover, there
is a strictly positive interrelation between OPG/RANKL
ratio and joint swelling index, as well as health assess-
ment questionnaire (HAQ) [11]. Therefore, to change
the ratio of OPG/RANKL might stop or at least slow
down the deterioration of this disease.
Our results demonstrated that LLDT-8 up-regulated the
OPG expression on CD3+ T lymphocytes in peripheralblood of RA patients, leading to the increased OPG/
RANKL ratio on CD3+ T cells both in peripheral blood
and in synovial fluid. Meanwhile, LLDT-8 treatment sup-
pressed the secretion of inflammatory cytokines, such as
IL-1β, IL-6, IL-21 and IL-23, but promoted the production
of anti-inflammatory cytokine IL-10, in order to regulate
RANKL/RANK/OPG system. The ratio of OPG/RANKL
was significantly increased by LLDT-8, which indicated
that corresponding improvement might be achieved in the
patients under LLDT-8 treatment.
The mechanism on which LLDT-8 regulates OPG/
RANKL ratio and inhibits osteoclastic activation may in-
volve several aspects. RANKL expression is regulated by
various cytokines, such as bone resorbing factor, gluco-
corticoid, 1α,25(OH)2D3, IL-1, IL-6, IL-11, IL-17, TNF-
α, PGE2, PTH and so on. They carry out their functions
via inducing RANKL expression in osteoblasts, and thus
promote bone resorption [12]. IL-21 enhances osteoclas-
togenesis in vitro by up-regulating the expression of
RANKL in CD4+ T cells in CIA mice as well as CD4+ T
cells and fibroblast-like FLS of RA patients [13]. Besides,
IL-23 also induces RANKL expression in FLS of RA pa-
tients through MEK1/2, NF-κB and STAT3 signaling
pathway, which was reported to involve in the pathogen-
esis of RA [14]. The serum level of IL-23 is associated
with the symptom of RA. In contrast, IL-10 suppresses
RANK-induced osteoclastogenesis and selectively inhibits
Figure 6 LLDT-8 decreased the number of TRAP-positive cells. RAW264.7 cells were cultured in the presence of RANKL (50 ng/ml) and
M-CSF (50 ng/ml) with various concentrations of LLDT-8 (0, 12.5, 25 and 50 nM, respectively) for 6 days, the cells of the control group were
cultured without RANKL and M-CSF. All the cells were fixed and stained for TRAP according to the manufacturer’s instructions on day 1, 2, 3 and
6. Osteoclast formation was determined to be TRAP-positive staining multinuclear cells using light microscopy. The total number of TRAP-positive
cells in each well was counted on day 1 (A), 2 (B), 3 (C) and 6 (D), respectively. #p < 0.05, ##p < 0.01, and ###p < 0.001, compared with the control
group; *p < 0.05,**p < 0.01, compared with LLDT-8-non-treated (0 nM) group.
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the transcription of TREM-2 [15]. IL-4 also serves as a
protective cytokine in RA, which inhibits osteoclasts for-
mation by stimulating osteoblasts to produce OPG [16].
These studies confirmed that pro-inflammatory cytokines,
IL-1, IL-6, IL-17, IL-21, IL-23 and TNF-α induce osteo-
clasts formation via RANKL signaling pathway; on the
other hand, anti-inflammatory cytokines like IL-4 and IL-
10 block RANKL signaling pathway and in turn inhibit os-
teoclasts formation. In our study, we showed that LLDT-8
enhanced the ratio of OPG/RANKL by increasing OPG
expression and down-regulated the production of IL-1β,
IL-6 and IL-21 in PBMCs and SFMCs. LLDT-8 also sup-
pressed the production of IL-23 in PBMCs, but promoted
IL-10 secretion in PBMCs and SFMCs. Previous studies
reported that LLDT-8 inhibited TNF-α and IL-17 secretion
in PBMCs and SFMCs but up-regulated IL-4 expression in
CD4+ T cells. All these results suggested that LLDT-8
probably regulated RANKL/RANK/OPG system by up-
regulating the expression of osteoclasts inhibitive factors in
RA patients. These data also explained how LLDT-8 exerts
its function on anti-osteoclastogenesis in RA patients.
Up to now, it is not easy to collect mature osteoclasts
from animal or human tissues. The osteoclasts requiredwere usually obtained from differentiation of osteoclastic
progenitor. Recently, methods of inducing neoblast to
differentiate into osteoclast in vitro is well established,
for example, co-culturing marrow stroma cell with myelo-
moncyte, stimulating myelomoncyte with culture medium
of marrow stroma cell, and inducing myelomoncyte and
mice RAW264.7 cell with mice recombination RANKL.
Among them, the osteoclasts induced by RANKL were
larger in both volume and number. This method was eas-
ier to operate compared with other methods [17].
RAW264.7 is mice mononuclear macrophage cell line,
and can differentiate into osteoclast-like cells in the pres-
ence of RANKL and M-CSF. During our research we ob-
tained osteoclasts easily and steadily by using this method.
Our results showed that RAW264.7 cells differentiated
into TRAP-positive osteoclast-like cells in the presence of
RANKL and M-CSF, and LLDT-8 decreased the osteoclas-
togenesis. To reveal its mechanism of action, we further
examined the signaling pathway involved in RANK/
RANKL/OPG system under LLDT-8 treatment. NF-κB
plays an essential role in the process of osteoclasts differ-
entiation and anti-apoptosis. NF-κB p50 and p52 ex-
pression is essential for RANK-expressing osteoclast
precursors to differentiate into TRAP-positive osteoclasts
Figure 7 The effect of LLDT-8 on key proteins of the downstream signaling pathways of RANKL. RAW264.7 cells were treated with LLDT-8
(0 and 50 nM, respectively) for 4 hours, then induced by culture medium supplemented with 50 ng/ml RANKL for 0, 10, 30 and 60 min, respectively.
The protein levels of p-IκB, p-P38, p-JNK, p-ERK and p-Akt were detected by western blotting. (A) Immunoblots of the key proteins. RANKL significantly
increased the levels of phosphorylation of I-κB, P38, JNK, ERK and Akt in a short time. (B) Relative expression of the key proteins. Compared with the
control group, LLDT-8 markedly inhibited the expression of p-IκB induced by RANKL. However, it had little effect on the expression of p-P38、p-JNK、
p-ERK and p-Akt induced by RANKL. **p < 0.01, ***p < 0.001, compared to the control group (0 nM) at the same time point.
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kines [18]. Interestingly, we found that LLDT-8 inhibits
the expression of p-IκB which could be induced by
RANKL. This indicates LLDT-8 probably decreases
RANKL-induced osteoclastogenesis by suppressing NF-κB
signaling pathway.
Several signaling molecules that promote the differen-
tiation and maturation of osteoclasts participate in
RANKL signaling pathway. Mitogen activated protein
kinase (MAPK) is one of the serine/threonine phosphor-
ylating kinases. There are many forms of MAPK, includ-
ing extracellular regulated kinase (ERK), Jun N-terminal
kinase/stress-activated protein kinase (JNK/SAPK) p38
MAPK [19], and etc. These kinases are activated in
RANKL downstream, and promote osteoclasts differen-
tiation. M-CSF facilitates RANKL-induced activation of
c-fos and ERK1/2 phosphorylation, in turn increases the
activity of osteoclasts. Studies showed that the functionof M-CSF could be blocked by MEK inhibitor PD98059
[20]. As c-Jun is an essential transcription factor for
osteoclast differentiation in vivo, blockade of the JNK
and c-Jun pathway by SP600125 suppresses osteoclast
differentiation. In addition, RANKL-induced osteoclasts
differentiation is markedly inhibited by over-expression
of dominant-negative JNK1 or dominant-negative c-Jun
[21]. Bone resorption area and number of osteoclasts in vivo
were significantly decreased by the treatment of FR167653,
a P38 MAPK inhibitor [22]. Phosphatidylinositol-3 kinase
(PI3K) plays an important role in multiple biological pro-
cesses such as proliferation, survival, migration, secretion
and etc. The activity of PI3K is regulated by RANK
through upstream Src, which is an intracytoplasm protein
kinase. Then Akt is activated, which further facilitates os-
teoclasts differentiation. When RAW264.7 and macro-
phage precursor cells (BMMs) were treated with RANKL,
a higher steady-state level of IP3 was observed in
Shen et al. BMC Complementary and Alternative Medicine  (2015) 15:77 Page 10 of 10RAW264.7 cells. In BMMs, the inhibition of phospholip-
ase C (PLC) with U73122, a specific inhibitor of PLC and
IP3Rs, suppressed the generation of RANKL-induced
multinucleated cells and decreased the bone-resorption
rate [23]. In our study, significant effect of LLDT-8 on the
expression of p-P38, p-JNK, p-ERK and p-Akt induced by
RANKL were not observed. Real-time PCR should be
used to further reveal the role of LLDT-8 on the down-
stream signaling pathways of RANKL, including NF-κB
pathway. Moreover, how LLDT-8 affects NF-κB pathway
is still not clear. Thus, further research needs to be done,
in order to clarify the effect of LLDT-8 on the downstream
signaling pathways of RANKL.
Conclusions
In conclusion, our results showed that LLDT-8 plays an
important role on anti-osteoclastogenesis effect in RA
probably through regulating RANKL/RANK/OPG sys-
tem and its downstream signaling pathway as well as
cytokine productions. However, more details of the
mechanisms of the multi-function of LLDT-8 still need
to be studied. There may be a prospect of applying
LLDT-8 in the treatment of RA.
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